Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: A single-center experience in Korea

International Journal of Hematology

Volumn 81, Issue 1, 2005, Pages 69-74

  Choi, Su Mi ^a   Lee, Dong Gun ^a   Choi, Jung Hyun ^a   Yoo, Jin Hong ^a   Kim, Yoo Jin ^a   Sun, Hee Park ^a   Park, Sun Nam ^a   Min, Chang Ki ^a   Lee, Seok ^a   Kim, Hee Je ^a   Kim, Dong Wook ^a   Lee, Jong Wook ^a   Min, Woo Sung ^a   Shin, Wan Shik ^a,b   Kim, Chun Choo ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

CMV antigenemia; Cytomegalovirus; Ganciclovir; Preemptive therapy

Indexed keywords

ACICLOVIR; BUSULFAN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIGEN PP65; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; HYPERIMMUNE GLOBULIN; MELPHALAN; METHOTREXATE; PROCARBAZINE; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BACTEREMIA; CHICKENPOX; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HIGH RISK POPULATION; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NEUTROPENIA; PNEUMOCYSTOSIS; PNEUMONIA; SINUSITIS; SKIN INFECTION; SOFT TISSUE INFECTION; SUPERINFECTION;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; KOREA; MALE; MIDDLE AGED; RISK MANAGEMENT; TRANSPLANTATION, HOMOLOGOUS;

EID: 19944434167     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.A30402     Document Type: Article

References (24)

1. Meyers JD. Prevention and treatment of cytomegalovirus infection after marrow transplantation. Bone Marrow Transplant. 1988;3:95-104.
2. Miller W, Flynn P, McCullough J, et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood. 1986;67:1162-1167.
3. Kim YK, Kim DW. Seroepidemiology of human cytomegalovirus in healthy adults measured by means of the anticomplement immunofluorescence technique [in Korean]. Korean J Infect Dis. 1992;24:87-92.
4. Hahn JS, Lee SJ, Park WK, Ko YW, Kim HO, Lee SY. A survey on the cytomegalovirus antibodies in blood donors and the diseased. Korean J Blood Transfusion. 1990;1:21-34.
5. Boeckh MJ, Ljungman P. Cytomegalovirus infection after hemopoietic stem cell transplantation. In: Bowden RA, Ljungman P, Paya CV, eds. Transplant Infections. 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2003.
6. Grob JP, Grundy JE, Prentice HG, et al. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections. Lancet. 1987;1:774-776.
7. Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98:2043-2051.
8. Einsele H, Hebart H, Kauffmann-Schneider C, et al. Risk factors for treatment failure in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant. 2000;25:757-763.
9. Wang FZ, Larsson K, Linde A, Ljungman P. Human herpesvirus 6 infection and cytomegalovirus-specific lymphoproliferative responses in allogeneic stem cell transplant recipients. Bone Marrow Transplant. 2002;30:521-526.
10. DesJardin JA, Gibbons L, Cho E, et al. Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. J Infect Dis. 1998;178:1783-1786.
11. Dockrell DH, Prada J, Jones MF, et al. Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease. J Infect Dis. 1997;176:1135-1140.
12. Yoo JH, Shin WS, Choi JH, et al. Clinical analysis of cytomegalovirus antigenemia after allogeneic bone marrow transplantation and a suggestion of a guideline to initiation of therapy. Korean J Hematol Stem Cell Transplant. 1997;2:43-49.
13. Lee DG, Park ST, Choi SM, et al. Prevalence of human herpesvirus-6B in Korean hematopoietic stem cell transplantation recipients. Mol Cells. 2003;16:307-315.
14. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094-1097.
15. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88:4063-4071.
16. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood. 1994;83:1971-1979.
17. Mori T, Okamoto S, Matsuoka S, et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000;25:765-769.
18. Kanda Y, Mineishi S, Saito T, et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplant. 2001;27:437-444.
19. Small TN, Papadopoulos EP, Boulad F. Outcome of pre-emptive or prophylactic anti-viral therapy to prevent CMV disease following T cell depleted related or unrelated BMT [abstract]. Blood. 2001;98:S394a. Abstract 1659.
20. Manteiga R, Martino R, Sureda A, et al. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience. Bone Marrow Transplant. 1998;22:899-904.
21. Humar A, Lipton J, Welsh S, Moussa G, Messner H, Mazzulli T. A randomized trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients. Bone Marrow Transplant. 2001;28:485-490.
22. Meijer E, Boland GJ, Verdonck LF. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev. 2003;16:647-657.
23. Krause H, Hebart H, Janh G, Muller CA, Einsele H. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant. 1997;19:1111-1116.
24. Boeckh M, Bowden RA, Gooley T, Myerson D, Corey L. Successful modification of a pp-65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood. 1999;93:1781-1782.